Skip to main content
Midas Edge

MANGOCEUTICALS INC

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

MGRX$0.20+1.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statement of Changes in Stockholders' Equity (Deficit)

MANGOCEUTICAL, INC.

Statement of Changes in Stockholders' Equity (Deficit)

For the Years Ended December 31, 2023 and 2022

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ Equity
SharesAmountCapitalDeficit(Deficit)
Balance, December 31, 20218,000,000$800$181$(17,701)$(16,720)
Issuance of common stock for services3,365,000337539,728-540,065
Issuance of units for cash2,000,0002001,999,800-2,000,000
Options and warrants vested for services--234,088-234,088
Warrants for services cancelled--(151,821)-(151,821)
Imputed interest--6,473-6,473
Net loss---(1,998,055)(1,998,055)
Balance, December 31, 202213,365,000$1,337$2,628,449$(2,015,756)$614,030
Issuance of common stock for services1,780,0001781,530,473-1,530,651
Issuance of common stock for cash5,250,0005256,199,475-6,200,000
Imputed interest related party loan repayment--(6,473)-(6,473)
Options and warrants vested for services--624,463-624,463
Warrants exercised1,024,5001021,024,398-1,024,500
Net loss---(9,212,417)(9,212,417)
Balance, December 31, 202321,419,5002,14212,000,785(11,228,173)774,754
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.